



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C08B 15/00, 37/04, 37/08	A1	(11) International Publication Number: WO 00/27886 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/EP99/08480 (22) International Filing Date: 9 November 1999 (09.11.99) (30) Priority Data: MI98A002443 ✓ 11 November 1998 (11.11.98) IT (71) Applicant (for all designated States except US): AQUISITIO S.P.A. [IT/IT]; Piazzale Aquileia, 8, I-20144 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): BARBUCCI, Rolando [IT/IT]; Piazzale Aquileia, 8, I-20144 Milano (IT). SPOROLETTI, Giancarlo [IT/IT]; Piazzale Aquileia, 8, I-20144 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CROSS-LINKING PROCESS OF CARBOXYLATED POLYSACCHARIDES		
(57) Abstract A process for the preparation of cross-linked polysaccharides containing carboxy groups, allowing complete control of cross-linking degree as well as high reproducibility in terms of constant characteristics of the final product. The process comprises a first step: activation of the carboxy groups in anhydrous aprotic solvent and then the reaction with a polyamine. The obtained cross-linked polysaccharide may be subjected to sulphation of the five hydroxy groups.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

"CROSS-LINKING PROCESS OF CARBOXYLATED
POLYSACCHARIDES"

The present invention refers to a cross-linking process of carboxylated
5 polysaccharides.

The process of the invention provides a high degree of reproducibility of
the obtained products, in terms of cross-linking degree, homogeneity of the
distribution of the cross-linking chains, and chemico-physical characteristics of
the products and the technological characteristics of the articles obtained
10 therefrom.

The reproducibility is particularly important for the applications in the
medical, pharmaceutical and dermo-cosmetic fields.

The invention further refers to the products obtainable by said process
and their applications in the medical, pharmaceutical and dermo-cosmetic
15 field.

Background of the invention

The use of macromolecules in the medical/pharmaceutical field and, more
recently, in the dermatological-cosmetic field, is well established.
Macromolecules are used in the preparation of pharmaceutical formulations as
20 thickening agents, lubricants, gastro-resistant film coating agents, particularly
in the preparation of capsules, gel, colloids and of different devices (e.g.
contact lenses, gauzes, etc.). Macromolecules are also used in the preparation
of controlled-release formulations of active ingredients.

Reviews of their characteristics and pharmaceutical uses are reported in
25 1) C. Hansch et Al. Editors - "Comprehensive Medicinal Chemistry" -
Pergamon Press, Oxford, 1990 - Vol. 1-6;
2) A. Wade and P.J. Wellers Editors - "Handbook of Pharmaceutical Excipients
" - Ed. 1994 - The Pharmaceutical Press.

Said macromolecules belong to different chemical families and may be either synthetic, or natural or semi-synthetic.

Examples of synthetic macromolecules include polyvinylpyrrolidone, polyoxyethylenealkyl ethers, polyvinyl alcohols, polymethacrylates. Examples
5 of natural macromolecules include native hyaluronic acid (HY) and cellulose.

Examples of semi-synthetic macromolecules include carboxyalkylcelluloses, widely used in the food and personal care industries. These macromolecules are characterized by a linear or poorly branched structure.

10 A very important modification for increasing the chemical, enzymatic and mechanical strength is provided by cross-linking, which may be carried out both on synthetic and natural (more or less already modified) polymers.

Examples of cross-linked polymers include polymers used for the gastro-protection of tablets or capsules (polymethacrylates), as well as polymers used
15 as emulsifiers, suspending agents, tablet hardeners (Carbopol), cross-linked hyaluronic acids, hereinafter discussed.

For the considered applications, and particularly for the preparation of invasive medical devices which have to be administered parenterally, said polymers must meet a number of requirements, of technical and regulatory
20 kind.

The technical requirements include:

- 1) high biocompatibility;
- 2) resistance to enzymatic systems, both tissular or plasmatic (for injectable compositions) and gastrointestinal (for oral compositions).

25 In some cases a gradual degradation, for instance for the controlled release of a medicament, may be desirable.

This resistance is particularly important when the macromolecule is present in compositions/articles that must last for a long time, e.g. substitutes

of the synovial liquid, films, sponges or gels as tissular antiadhesives in different kinds of surgery; in tissular engineering (artificial organs); artificial skins, in the treatment of burns and generally in aesthetic surgery;

- 3) moldability into different shapes (gels, films, sponges, etc.);
- 5 4) possibility to be sterilized chemically or physically without changing the product structure.

According to the regulatory requisites, the composition of the different production batches must be kept constant within very narrow limits; this implies that the production methods are standardized and that the base
10 components have a very low intrinsic variability.

A possible cause of dishomogeneity for macromolecules derives from the dispersion of molecular weights. Said dishomogeneity becomes even higher as a consequence of cross-linking. This may be a serious drawback depending on the field of use and the applicative purposes of the final product.

15 EP-A-566118 (Kimberly-Clark) discloses cross-linked polysaccharides to be used as super-absorbents for diapers and similar articles.

The process described therein is based on the cross-linking of cellulose by formation of intermolecular amides, esters or ethers between polyamines, polyols or mixtures thereof and the carboxy group of polysaccharides.

20 The reaction is carried out by heating at about 80°C the mixture of the polysaccharide with the polyol and/or polyamine. This process is certainly economic and suitable for large scale production where the reproducibility requirements are less stringent.

US 5465055 discloses cross-linked polysaccharides (hyaluronic acid and
25 alginic acid) obtained by esterification of COOH of the polysaccharide and OH groups of other molecules, without insertion of cross-linking arms.

WO 91/9119 discloses microcapsules for islets of Langerhans as biohybrid organs, consisting of alginic acid cross-linked with barium ions.

EP 190215 discloses the cross-linking of different polymers (carboxylated starches, dextran, celluloses) with di- or poly-functional epoxides.

The following cross-linking agents for hyaluronic acids have been proposed:

- 5 polyfunctional epoxides are disclosed in US 4716224, 4772419, 4716154;
polyalcohols are disclosed in US 4957744;
divinylsulfone is disclosed in US 4605691, 4636524;
aldehydes are disclosed in US 4713448 and 4582865;
carboxamides are disclosed in US 5356833;
- 10 polycarboxylic acids are disclosed in EP-A-718312.

Disclosure of the invention

The invention refers to a process for the preparation of cross-linked polysaccharides containing carboxy groups, allowing complete control of cross-linking degree as well as high reproducibility in terms of constant
15 characteristics of the final product.

The process of the invention comprises:

- a) activation of the carboxy groups of the polysaccharide by reaction with suitable carboxy activating agents in anhydrous aprotic solvent;
- b) reaction of the carboxy activated polysaccharide with a polyamine.

20 The obtained cross-linked polysaccharide, if desired, may be subjected to sulphation or hemisuccinylation of the free hydroxy groups.

The products obtainable by the process of the invention may also be complexed with metal ions such as zinc, copper or iron ions.

The carboxy-containing polysaccharide which may be used according to
25 the invention may be of natural, synthetic or semi-synthetic origin. Examples of said polysaccharides include Hyaluronic acids (obtained from tissues or bacteria), carboxymethyldextran, carboxymethylcellulose, carboxymethyl-starch, alginic acids, cellulosic acid, N-carboxy-methyl or butyl glucans or


chitosans; heparins with different molecular weights, optionally desulphated and succinylated, dermatan sulphates, Chondroitin sulphates, heparan sulphates, polyacrylic acids.

Hyaluronic acids, carboxymethylcellulose, heparins, alginic acids and
5 polyacrylic acids are particularly preferred.


Said cross-linked polymers, obtained by different methods, are known and have been proposed for several uses (see, for instance, EP 566118, WO91/9119, US 5465055, EP 190215, EP 718312, US 4716224 discussed above).

10 The carboxy activating agents are usually those used in the peptide chemistry: examples of suitable agents include carbonyldiimidazole, carbonyltriazole, chloromethylpyridylum iodide (CMP-J), hydroxybenzotriazole, p-nitrophenol p-nitrophenyltrifluoroacetate, N-hydroxysuccinimide and the like. The use of chloromethylpyridylum iodide is
15 particularly preferred.


The polyamines have preferably the following general formula:



wherein R_1 and R_2 , which are the same or different, are hydrogen, C_1 - C_6 alkyl, phenyl or benzyl groups, A is a C_2 - C_{10} alkylene chain, preferably a C_2 -
20 C_6 alkylene chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy, amino groups; a polyoxyalkylene chain of formula



wherein n is 2 or 3 and m is an integer from 2 to 10; a C_5 - C_7 cycloalkyl group; an aryl or hetaryl group, preferably 1,3 or 1,4-disubstituted benzene. A is
25 preferably C_2 - C_6 linear alkylene or a chain of formula



The cross-linking reaction is preferably carried out in a solvent selected from tetrahydrofuran, dimethylformamide or dimethyl sulfoxide, and the

polysaccharide is preferably salified with a lipophilic cation, for example tetralkylammonium or other lipophilic organic bases.

The transformation of inorganic salts such as sodium salts, into suitable organic lipophilic salts may be carried out by known ion-exchange methods in
5 homogeneous phase or by precipitation of the acidic component, followed by recovering of the latter and salification with the desired organic base.

The activation reaction of the carboxy groups is carried out in homogeneous phase and in anhydrous polar aprotic solvent.

The polyamine diluted in the same anhydrous solvent, is added to the
10 solution of the activated ester, keeping the temperature from 0°C to 30°C. The cross-linking reaction times range from 1 to 12 hours, also depending on the optional presence of suitable basic substances (e.g. triethylamine).

Generally, the final product is recovered by precipitation of the organic salt adding a different solvent to the reaction solvent or by evaporation of the
15 latter, followed by centrifugation, washing with distilled water, repeated dispersions in the solutions of the desired alkali (for instance sodium, potassium), subsequent washing with water and final drying of the alkaline salt under vacuum or by lyophilization.

The cross-linking degree (C.L.D) may range within wide limits and may
20 be adjusted by changing the amount of the carboxy activating agents, since the activation and the cross-linking reaction are substantially quantitative.

The cross-linked polysaccharides obtained according to the invention may be subjected to sulphation reaction of the hydroxy groups possibly present, usually by reaction with the pyridine-sulfur trioxide complex in
25 dimethylformamide.

The reaction is carried out in heterogeneous phase at a temperature of 0-10°C for times ranging from about 0,5 to about 6 hours.

The sulphation degree obtained is comprised within wide limits with

respect to the total of the hydroxy groups and it may be adjusted by changing the temperature and reaction times. Generally, the sulphation degree (defined as equivalents of sulphate groups/g) may range from 1×10^{-6} to 6×10^{-6} , preferably it is of 2×10^{-6} eq/g for a cross-linking degree of 0.5.

5 The cross-linked polymers obtained according to the invention, optionally sulphated, are able to complex metal ions such as zinc, copper or iron ions.

Said complexes may be obtained by dissolving or dispersing until complete swelling the product in water and adding under stirring, preferably at room temperature, a concentrated solution of an organic or inorganic metal
10 salt, e.g. CuCl_2 , ZnCl_2 , $\text{Fe}_2(\text{SO}_4)$; after stirring for 12-24 hours, the complex is recovered by centrifugation or by precipitation following the addition of a different solvent (for example ethanol or acetone) or evaporation under vacuum; the recovered crude product is thoroughly washed with distilled water so as to remove the excess ions. The complexes are then lyophilized. The
15 content of metal ions varies depending on the used operative conditions, particularly the polymer to ion molar ratios; concentration and pH of the solutions; reaction times and particularly cross-linking degree.

The process of the invention, by suitably adjusting the cross-linking and/or sulphation degree, allows the preparation of cross-linked carboxylated
20 polysaccharides in a wide range of shapes, characterized by different properties such as viscoelasticity, hydration degree, complexing ability towards metal ions, ability to form hydrogels, moldability in films or sponges, mechanical strength of the final materials.

This allows their use in many medical fields, in the human and veterinary
25 field, and in dermo-cosmetology.

The following examples further illustrate the invention.

EXAMPLE 1:

Carboxymethylcellulose gel 100% cross-linked with 1,3-diaminopropane.

1,2 x 10⁻³ moles, with reference to the disaccharide unit of carboxymethyl cellulose TBA salt, were dissolved in 30 ml of DMF under N₂ and with stirring. 0.32 g of chloromethylpyridylum iodide (1.2 x 10⁻³ moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of 0° C with ice.

The molar ratio was 1 to 1 as carboxymethyl cellulose has one functional carboxylic group per disaccharide unit. After 20 minutes the solution was added with 2 ml of cross-linking 1,3-diaminopropane (0.006 moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H₂O to completely swell.

Alternating washings with EtOH and H₂O were then carried out. After the last washing with EtOH, the product was freeze-dried.

- I.R. (film; cm⁻¹): 1650(-CO-NH-); no bending -COO⁻ at 1.400 about.
- SD (Swelling Degree, in water and r.t., after 15'; gravimetric determination; calculated according to: $SD = \frac{W_s - W_d}{W_d} \cdot 100$, where:

W_s = weight of hydrated gel; W_d = weight of dry gel): 7.000

- SEM (Scanning Electron Microscopy): the structure looks compact, with 15-35μ pers.
- The product surface, by rabbit PRP (Platelet Rich Plasma) exposure, shows a very reduced presence of platelets or aggregates in comparison with equivalent product obtained by low density polypropylene (EC reference standard).

EXAMPLE 2:

Carboxymethyl cellulose gel 50% cross-linked with 1,3-diaminopropane.

1,2 x 10⁻³ moles, referred to the disaccharide unit of carboxymethyl cellulose, were dissolved in 30 ml of DMF under N₂ and with stirring. 0.24 g of chloromethylpyridylum iodide (1.2 x 10⁻³ moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of 0° C with ice. The

molar ratio was 2/1.

After 20 minutes the solution was added with 2 ml of cross-linking 1,3-diaminopropane (3×10^{-3} moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF,
5 then placed in H_2O to completely swell.

Alternating washings with EtOH and H_2O were then carried out. After the last washing with EtOH the product was freeze-dried.

- I.R. (film; cm^{-1}): 1650($-\underline{CO}-NH-$); no bending $-\underline{COO}^-$ at 1.400 about.
- SD: 8.000
- 10 - SEM: presence of 13-25 μ pers.
- Platelet adhesion: as reported in Example 1.

EXAMPLE 3:

Alginic acid gel 50% (100% with reference to disaccharide units) cross-linked with 1,3-diaminopropane.

- 15 The TBA salt of alginic has been prepared from the sodium salt by ionic exchange on strong cationic resin (Dovex) in H^+ form (i.e. acidic form), followed by neutralization with tetrabutylammonium hydroxide (TBA-OH) and final liophylisation.

1,2 $\times 10^{-3}$ moles, referred to the monosaccharide unit, were dissolved in 30
20 ml of DMF under N_2 and under stirring. 0.36 g of chloromethylpyridylum iodide ($1,2 \times 10^{-3}$ moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of $0^\circ C$ with ice. The molar ratio was 1/1.

After 20 minutes the solution was added with 6×10^{-3} moles of cross-linking 1,3-diaminopropane (0.024 moles), and immediately after also with 0.5
25 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H_2O to completely swell.

Alternating washings with EtOH and H_2O were then carried out. After the last washing with EtOH the product was freeze-dried.

- IR (film; cm^{-1}): 1635 (broad) ($-\text{CO}-\text{NH}-$): 1.400, about ($-\text{COO}^-$).
- SD: 5.000
- SEM: the structure looks compact and without pores.

EXAMPLE 4:

- 5 Preparation of hyaluronic acid cross-linked with C.L.D. = 0.05 (5% of available carboxy groups). Cross-linking agent: 1,3-propanediamine.

Hyaluronic acid sodium salt (1×10^{-3} mol., with reference to the disaccharidic unit) were transformed in TBA salt, according to one of the following methods:

- 10 a) 1% aqueous solution of sodium hyaluronate is transformed in H^+ form by H^+ cationic strong resin (Amberlite IR 120); the final solution is treated by a 0,5% solution of TBA-OH to about $\text{pH}=9$.
- b) 1% aqueous solution of sodium hyaluronate is transformed in TBA salt solution by treating with a cationic weak resin in TBA^+ form.
- 15 (Amberlite IRC 50)

In both cases, the final solutions are lyophilised. The TBA salt is then dissolved in 15 ml of anhydrous DMF, under N_2 , and – at 0°C - 0,02 g of chloromethypyridylum Iodide (CMPJ) in 2 ml of anhydrous DMF, are added dropwise to the stored solution of TBA salt.

- 20 The reaction mixture was then added with 0.1 ml of triethylamine and, then, dropwise, with a solution of 1,3-diaminopropane ($d= 0.88$, in large excess, so as to make cross-linking of the activated carboxy groups easier) in 2 ml of anhydrous DMF. When the addition was over, the reaction mixture was stirred for at least 30' and the solvent was then removed under reduced
- 25 pressure, the residue was then taken up with DMF, which was subsequently removed by distillation; the residue was then treated with ethanol, ethanol-water and finally with water.

The product was then lyophilised and the residue subjected to analysis.

IR (film; cm^{-1}): 1630 ($-\underline{\text{CO}}-\text{NH}$); 1740 ($-\underline{\text{COOH}}$, polysaccharide); 3200 ($-\text{NH}-$).

SD (Swelling Degree, in water and r.t., after 15'; gravimetric

5 determination; calculated according to: $\text{SD} = \frac{W_s - W_d}{W_d} \cdot 100$, where:

W_s = weight of hydrated gel; W_d = weight of dry gel): 31.000

Cross-linking degree: 0.05 (5% of initially available carboxy groups).

EXAMPLE 5:

10 Preparation of hyaluronic acid cross-linked with C.L.D. = 0.05 (5% of the available carboxy groups). Cross-linking agent: 1,6-diaminohexane.

Activator: chloromethylpyridylum iodide.

According to the procedure and conditions reported in Example 4, using the same HY and the same activator, but 1,6-diaminohexane instead of 1,3-
15 diaminopropane, the cross-linked derivative was obtained.

IR (film; cm^{-1}): 1630 ($-\underline{\text{CO}}-\text{NH}$); 1740 ($-\underline{\text{COOH}}$ polysaccharide); 3200 ($-\text{NH}-$).

EXAMPLE 6:

Preparation of cross-linked hyaluronic acid, with C.L.D. = 0.05 (5% of
20 the available carboxy groups). Cross-linking agent: 0.0'-bis-(2-aminopropyl)PEG500. Activator: chloromethylpyridylum iodide

According to the procedure and conditions reported in Example 4 and using the same activator, but 0.0'-bis-(2-aminopropyl)PEG500 instead of 1,3-diaminopropane, the cross-linked derivative was obtained.

25 IR (film; cm^{-1}): 1630 ($-\underline{\text{CO}}-\text{NH}$); 1740 ($-\underline{\text{COOH}}$ polysaccharide); 3200 ($-\text{NH}-$).

SD: 31.000

EXAMPLE 7:

Preparation of cross-linked hyaluronic acids, with C.L.D.= 0.3 (30% of the available carboxy groups). Cross-linking agent: 1,3-propanediamine. Activator: chloromethylpyridylium iodide.

5 0.6 g of hyaluronic acid tributylammonium salt (1×10^{-3} mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.08 g of chloromethylpyridylium iodide (3.5×10^{-4} mol) dissolved in 2 ml of DMF were added dropwise to the stirred solution kept at 0°C. The molar ratio was therefore about 3/1.

10 After 20 minutes 2 ml of 1,3-diaminopropane (0.024 mol) were added, followed immediately by 0.5 ml of triethylamine. A solid, gelatinous product was obtained, the product was then swelled with water and washed again with ethanol.

The final product, after lyophilisation, shows at the scanning microscope
15 an irregular pattern with smooth zones alternating to spongy zones.

The cross-linking degree was 0.3 (30% of initially available carboxy groups)

IR (film; cm^{-1}): 1740 ($-\text{COOH}$); 1630 ($-\text{CO-NH}$); 1610 ($-\text{COO-}$); 1560 ($-\text{CO-NH-}$)

20 **EXAMPLE 8:**

Preparation of hyaluronic acid cross-linked with C.L.D.= 0.5 (50% of the available carboxy groups). Cross-linking agent: 1,3-propanediamine. Activator: chloromethylpyridylium iodide.

25 0.6 g of hyaluronic acid tributylammonium salt (HY TBA) (1×10^{-3} mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.15 g of chloromethylpyridylium iodide (CMPJ) (6×10^{-6} mol) dissolved in 2 ml of DMF were added dropwise to the solution, kept at 0°C. The molar ratio was 2HY.TBA:1 CMPJ. After 20 minutes, 2 ml of

1,3 diaminopropane (0.024 mol.) were added to the solution.

0.5 ml of triethylamine were added thereafter.

A solid, gelly-like product was obtained and thoroughly washed with DMF.

5 After evaporating DMF, the product was swelled in water and washed with ethanol before lyophilization.

The obtained product had a cross-linking degree of 0.5 and showed at the scanning microscope a grainy aspect interspaced by large meshes. At higher magnitudes, the two morphologies appear identical and show round-shaped
10 protrusions a few microns in diameter.

IR (film; cm^{-1}): 1740 ($-\text{COOH}$); 1630 ($-\text{CO-NH-}$); 1610 ($-\text{COO}^-$); 1560 ($-\text{CO-NH-}$);

The gels were subjected to swelling in PBS and the max swelling ability was evaluated.

15 SD= 23.500

NMR = (13 C; ppm): 29.3 and 39.8 ($-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ propanediamine link); 172.5 ($-\overset{\cdot}{\underset{\text{O}}{\parallel}}{\text{C}}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$)

The rheological properties evaluated on Bohlin VOR Rheometer, at the
20 temperature of $23 \pm 0.1^\circ\text{C}$, show that the dynamic elastic module G' (100Pa at 10Hz) identical at the two considered concentrations (10 and 20 mg/ml) is always higher than the viscous dynamic module (G'' 40 Pa for 20 mg at 10Hz and 20 Pa for 10 mg at 10Hz).

25 EXAMPLES 9 - 12

According to the methods disclosed in the previous examples, the cross-linked hyaluronic acid derivatives having the characteristics summarised in the following table 1, were obtained, starting from 1×10^{-3} mol (0.6 g) of hyaluronic

acid tributylammonium salt.

The obtained derivatives had the following properties:

TABLE I

Ex	Cross-linking agent (mol)	Amount (g) of CMPJ (mol)	Cross-linking degree	SD	NMR (13) (ppm)	I.R. (film) (cm ⁻¹)	Scanning Electron Microscopy (SEM)
9	1,3-propanediamine (0.024)	0,6g (1.210 ⁻³)	(100%)	13.200	29.3/39.8 (-CH ₂ -CH ₂ -CH ₂ -propanediamine link); 172.5 (-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -)	1630 (-CO-NH-); 1560 (-CO-NH-);	Homogeneous, undulated morphology.
10	0,0'-1-bis-(2-diaminopropyl) PEG 500 (0.022)	0,15g (6x10 ⁻⁴)	(50%)	9.000			Alternating smooth areas and meshes, circular protrusions a few microns in size.
11	0,0'-bis (2-aminopropyl) - PEG 800 (0.022)	0,15g (6x10 ⁻⁴)	(50%)	6.100			Two morphologically different zones, a first one undulated and a second with hole-like structures.
12	1,6-diaminohexane (0.023)	0,15g (6x10 ⁻⁴)	(50%)	8.000	169.46(-CO-NH- of cross-linking); 74.04/76.80/83.17/80.41(-CH ₂ - of cross-linking arm)	1740 (-COOH); 1630 (-CO-NH-); 1610 (-COO-); 1560 (-CO-NH-);	Smooth surface with protrusions having a few microns in size.

EXAMPLE 13:

Sulphation of 50% cross-linked HY,

The derivative obtained in example 8 was dispersed in 5 ml DMF under strong stirring and nitrogen atmosphere.

- 5 A solution of 1 g of SO₃/pyridine in mol of DMF was added at 0°C and stirred for 3 hours. The reaction was blocked by adding an excess of H₂O (50 ml) and the pH adjusted to 9 with 0.1M NaOH.

The product was thoroughly washed with ethanol and H₂O and then lyophilized.

- 10 The IR spectrum shows, in addition to the bands of the starting product, a peak at 1260 cm⁻¹ and a stronger band at 1025 cm⁻¹.

- The gel swells in PBS with SD = 33.000. Higher resolution ¹³C NMR spectrum shows the signals in H₂O at 37°C reported in table 2. The intensity of the NMR signals at 29.3 and 38.8 ppm (-CH₂-) and the signal at 172.5 ppm
15 (CONH) confirm a cross-linking degree of about 50%.

- The rheological properties are characterised by dynamic elastic modules G' (2500Pa with 20 mg and 1000 Pa with 10 mg at 10Hz) which are always higher than the dynamic viscous modules G'' (600Pa with 20 mg and 150 Pa with 10 mg at 10Hz) and much higher than the corresponding values obtained
20 with non-sulphated HY (13 at 50% - example 5). This compound has a thrombin time (TT) higher (61±5") than the control (14.0") and the corresponding not cross-linked (14.6").

The compound was also active in the PRP test using stressed rabbit.

TABLE 2

Table: ^{13}C Chemical shift

C-1	C-2	C-3	C-4	C-5	x-C=O	y-CH ₃	
103.5	57.3	85.4	71.3	78.7	178.0	25.3	ppm
C-1'	C-2'	C-3'	C-4'	C-5'	6-C=O		
105.9	75.2	76.4	82.8	78.6	176.2		ppm
1-CH ₂	2-CH ₂	3-CH ₂	6'-C=O	CROSS- LINKING			
39.8	29.3	39.8	172.5				ppm

5 **EXAMPLE 14:**

Sulphation of Alginic acid GEL

The cross-linked product after treatment with EtOH was freeze-dried to remove completely humidity and subjected to sulphation of the alcohol groups.

100 mg of cross-linked product dispersed in 5 ml of DMF were added
 10 with a SO₃-pyridine solution of (800 mg in 2 ml of DMF). The reaction should be carried out at 0° C, under nitrogen and with constant stirring for 2 hours.

It is mandatory for the product not to adsorb humidity, as it inhibits the reaction.

After 2 hours H₂O was added pH was adjusted to 9 by a 1M solution of
 15 NaOH, thereby freeing pyridine.

The thus sulphated product was purified in EtOH.

The analysis of purified products, shows:

- IR (film; cm⁻¹) 1263 (stretching SO)
- Equivalents of SO₃ groups/g gel (by toluidine complexes):

20 5% cross linked gel: 6×10^{-5}

50% cross linked gel: 2×10^{-5}

100% cross linked gel: 3×10^{-5}

SD

5% cross linked gel: 19×10^{-3}

50% cross linked gel: 9×10^{-3}

100% cross linked gel: 7×10^{-3}

5 EXAMPLE 15:

Using the same methodology, the sulphated derivatives of 50% cross-linked products according to example 10,11 and 12, have been synthesized.

Colorimetric characteristics of the sulphated derivatives are reported in table 3 together with that of the products deriving from examples 8 and 13.

TABLE 3

CROSSLINKED (50% DEGREE)	POLYMER CROSS-LINKING	ΔH_a [J/g]	T _g [°C]	ΔH_b [J/g]	Wt % water
C.L.Hyal – 1,3 (Ex. 8)		276	51	42	12
C.L.HyalS – 1,3 (Ex. 13)		357	64	53	16
C.L.Hyal – 1,6 (Ex. 12)		327	64	58	16
C.L.HyalS – 1,6		465	64	65	20
5 C.L.Hyal – P500.2NH ₂ (Ex. 10)		239	45	72	10
6 C.L.HyalS – P500.2NH ₂		384	69	113	16
7 C.L.Hyal – P800.2NH ₂ (Ex. 11)		179	73	30	10
8 C.L.HyalS – P800.2NH ₂		206	76	52	10
Hyal ITBA		164	-	130	5

ΔH_a [J/g]: water vaporization henthalpy

T_g [°C]:

enthalpy for thermal degradation process

ΔH_b [J/g]: glass transition temperate

Wt % water: % of water content, based on ΔH_a

EXAMPLE 16:

Suphation of carboxymethylcellulose gel.

Following the procedure and conditions reported in Example 14, the sulphated derivative was obtained.

5 - Equivalents of SO_3 groups/g:

a- CMC 5% cross linked: 8×10^{-6}

b- CMC 50% cross linked: 7×10^{-6}

c- CMC 100% cross linked: 4×10^{-6}

SD

10 a: 20×10^{-3}

b: 12×10^{-3}

c: 9×10^{-3}


CLAIMS

1. A process for the preparation of cross-linked polysaccharides containing carboxy groups, comprising:
 - 5 a) activation of the carboxy groups of the polysaccharide by reaction with suitable carboxy activating groups in anhydrous aprotic solvent;
 - b) reaction of the carboxy activated polysaccharide with a polyamine.
2. A process according to claim 1, wherein the polysaccharide is selected from Hyaluronic acids (obtained from tissues or bacteria),
 - 10 carboxymethyldextran, carboxymethylcellulose, carboxymethylstarch, alginic acids, cellulosic acid, N-carboxy-methyl or butyl glucans or chitosans; heparins with different molecular weights, optionally desulphated and succinylated, dermatan sulphates, chondroitin sulphates, heparan sulphates, polyacrylic acids.
- 15 3. A process according to claim 1 or 2, wherein the carboxy activating agent is selected from carbonyldiimidazole, carbonyltriazole, chloromethylpyridylum iodide (CMP-J), hydroxybenzotriazole, p-nitrophenol p-nitrophenyltrifluoroacetate, N-hydroxysuccinimide.
4. A process according to any one of claims 1 to 3, wherein the
 - 20 polyamines have the following general formula:



wherein R_1 and R_2 , which are the same or different, are hydrogen, C_1 - C_6 alkyl, phenyl or benzyl groups, A is a C_2 - C_{10} alkylene chain, preferably a C_2 - C_6 alkylene chain, optionally substituted by hydroxy, carboxy, halogen,

- 25 alkoxy, amino groups; a polyoxyalkylene chain of formula



wherein n is 2 or 3 and m is an integer from 2 to 10; a C_5 - C_7 cycloalkyl group; an aryl or hetaryl group, preferably 1,3 or 1,4-disubstituted benzene.

5. A process according to any one of claims 1 to 4, wherein the

polysaccharide is salified with lipophilic cations.

6. A process according to claim 5, wherein the lipophilic cation is tributyl or tetralkyl ammonium.
7. A process according to any one of claims 1 to 6, wherein the cross-
5 linking reaction is carried out in anhydrous dimethylformamide or tetrahydrofuran.
8. A process according to any one of claims 1 to 7, wherein the obtained cross-linked polysaccharide is further subjected to sulfation of the hydroxy groups by reaction with the pyridine/sulfur trioxide complex.
- 10 9. A process according to claim 8, wherein the sulfation reaction is carried out in dimethylformamide in heterogeneous phase at 0-10°C for times from about 0.5 to about 6 hours.
10. A process according to any one of claims 1 to 9, wherein the cross-linked, optionally sulfated polysaccharide, is further subjected to
15 complexation reaction with aqueous solutions of copper, zinc or iron ions.
11. Cross-linked polysaccharides obtainable by the process of claims 1 to 10.

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 99/08480

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C08B15/00 C08B37/04 C08B37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W0 98 08897 A (S.C.R.A.S.) 5 March 1998 (1998-03-05) see the whole document	1-7, 11
Y	EP 0 265 116 A (FIDIA) 27 April 1988 (1988-04-27) page 9, line 36 - line 44	1-7, 11
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 February 2000

Date of mailing of the international search report

23/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Lensen, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/08480

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PATENT ABSTRACTS OF JAPAN vol. 1997, no. 11, 28 November 1997 (1997-11-28) & JP 09 176204 A (KOBAYASHI KAZUKIYO ET AL.), 8 July 1997 (1997-07-08) abstract & DATABASE WPI Week 199737 Derwent Publications Ltd., London, GB; AN 399535 abstract</p>	1-7, 11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08480

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9808897 A	05-03-1998	FR 2752843 A AU 4121597 A EP 0922071 A NO 990935 A PL 331848 A	06-03-1998 19-03-1998 16-06-1999 15-04-1999 16-08-1999
EP 265116 A	27-04-1988	IT 1198449 B AT 163942 T AU 610087 B AU 7960087 A CA 1317287 A CN 1025035 B DE 3752176 D DE 3752176 T DK 536087 A ES 2115583 T FI 874504 A,B, HU 45734 A,B IL 84032 A IN 170958 A IN 170801 A JP 2648308 B JP 63105003 A KR 9202702 B NO 175374 B NZ 221994 A PH 26025 A PT 85908 A,B US 4957744 A ZA 8707559 A	21-12-1988 15-03-1998 16-05-1991 21-04-1988 04-05-1993 15-06-1994 16-04-1998 29-10-1998 14-04-1988 01-07-1998 14-04-1988 29-08-1988 20-11-1997 20-06-1992 23-05-1992 27-08-1997 10-05-1988 31-03-1992 27-06-1994 26-07-1990 29-01-1992 01-11-1987 18-09-1990 13-04-1988
JP 09176204 A	08-07-1997	NONE	